Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE (0.13%), DAX +0.00%, CAC40 +0.04%

Dec 23 ,2025

  • Synopsis

    • European equity market futures point to a mixed open. Asia equities higher for a second consecutive day Tuesday. Best gains in Australia, Taiwan and South Korea while Greater China and Southeast Asia more mixed. India flat in early trading. US futures slightly lower.

    • Reuters reports France's government will push lawmakers to approve emergency legislation to keep the state running into January after they failed to agree on a 2026 budget, a stopgap measure to avert a shutdown.

    • ECB's Schnabel told FAZ podcast on Mon she does not expect interest rates to be lifted for some time, barring any unforeseen events.

    • Meanwhile in the UK, British Chambers of Commerce said the UK's existing trade and cooperation agreement (TCA) was failing to help them grow their sales in the EU and a closer EU trade deal is a "strategic necessity" (Guardian). FT cites latest UK official house price figures for October showing that property prices contracted y/y in 18 of the 33 London boroughs, in contrast with a +1.7% house price increase across the UK.

    • Macro data include Spain Q3 final GDP, Nov PPI, Switzerland Dec economic sentiment index, Sweden Nov PPI, Belgium Dec CPI, Nov PPI with Finland Nov unemployment rate already on the tape.

    • A light corporate front sees Novo Nordisk (NOVO.B.DC) Wegovy pill approved in the US as first oral GLP-1 for weight management whilst Terveystalo (TTALO.FH) acquires Hohde Group with EV ~€88M.

    • Of note, Intea Fastigheter (INTEA.B.SS) EGM in connection with previously disclosed placing of class-D shares.

  • Politics/Macro/World News

    • Keir Starmer told closer EU trade ties 'strategic necessity' for UK firms - Guardian

    • ECB's Schnabel Doesn't Expect Rate Hikes in Foreseeable Future - FAZ

    • House prices fall in half of London boroughs - FT

    • UK Business Confidence in Post-Budget Recovery, Lloyds Says - Bloomberg

    • France rushes emergency budget law to avert shutdown after talks collapse - Reuters

    • Government's budget bill arrives on the floor of the Senate - Ansa

    • You cannot annex other countries, Danish and Greenlandic leaders tell Trump - Guardian

    • Finland Nov Unemployment Rate 9.7% vs consensus 9.6% and prior 9.6%

    • European Automobile Manufacturers' Association (ACEA) November new car registrations for EU + EFTA + UK +2.4% y/y

  • Top company news

    • Earnings

      • No major earnings

    • M&A

      • TRMD.A.DC (TORM Plc) -- Hafnia completes acquisition of 13.97% of TORM from Oaktree

      • ELIS.FP (Elis) -- announces acquisition of Adrett in Germany; price not disclosed

      • ORRON.SS (Orrön Energy) -- sells a portfolio of three solar energy projects in Germany for a total consideration of up to M€14

      • ORX.SS (Orexo) -- enters into agreement with Dexcel Pharma USA to divest US rights to Zubsolv

      • TTALO.FH (Terveystalo) -- acquires Hohde Group; EV of the target is ~€88M

      • INTEA.B.SS (Intea Fastigheter AB) -- agrees with Smedjan Samhällsfastigheter to acquire the new Ångermanland District Court which is currently being completed in Härnösand

      • SWP.FP (Sword Group) -- confirms the sale of its subsidiary Tipik to mci group for an undisclosed sum

      • BRE2.SS (Bredband2 i Skandinavien) -- Telia Company obtains all necessary approvals from authorities for recommended cash offer for Bredband2 i Skandinavien

    • Healthcare

      • REGN (Regeneron) -- Japan approves Regeneron's Dupixent for children aged 6 to 11 years with bronchial asthma

      • NOVO.B.DC (Novo Nordisk) -- Wegovy pill approved in the US as first oral GLP-1 for weight management

      • AMRX (Amneal Pharmaceuticals) -- mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA

      • AB.FP (AB Science) -- announces US patent for the use of masitinib for the treatment of sickle cell disease, expiring in November 2040

      • IRLAB.A.SS (IRLAB Therapeutics) -- receives regulatory and ethical approvals for Phase Ib study of IRL757 in Parkinson's Disease

    • Other

      • DOV.IM (doValue) -- launches the first contribution fund focused on state-guaranteed loans

      • TRMD.A.DC (TORM Plc) -- SEC filing: SCHEDULE 13D (Filed by Hafnia Ltd)

      • ALO.FP (Alstom) -- to supply 23 Coradia Stream electric trains with a 10-year maintenance contract to Hellenic Train in Greece; total value €393M

      • ORSTED.DC (Ørsted) -- announces Revolution Wind and Sunrise Wind receive lease suspension orders from US Department of the Interior's Bureau of Ocean Energy Management

      • TE.FP (Technip Energies) -- receives €250-500M authorization from Commonwealth LNG which includes the issuance of purchase orders for the key equipment needed for its 9.5 Mtpa liquefied natural gas (LNG) facility in Cameron Parish, Louisiana, USA

      • Trump administration cancels offshore wind leases; FanFuel, Coinbase to enter prediction markets in intraday themes

  • Data

    • Nikkei +0.02% to 50412.87

    • Hang Seng (0.28%) to 25729.71

    • Shanghai Composite (0.13%) to 3912.20

    • S&P futures (6.5) vs prior close of 6930.3

    • €-$ +0.0008 or +0.07% to 1.1771

    • $-¥ (0.95) or (0.61%) to 156.09

    • €-¥ (1.02) or (0.55%) to 183.69

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE